Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g 4 Regulatory News (MAV4)

Share Price Information for Maven I&g 4 (MAV4)

Share Price is delayed by 15 minutes
Get Live Data
50.00    0.00 (0.00%)
Bid:
49.00
Ask:
51.00
Spread: 2.00 (4.082%)
Market Cap: £83.71m
MAV4 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g 4 Share Chart

Statement re Offer for Subscription

10 Jan 2022 12:43

RNS Number : 9606X
Maven Income and Growth VCT 3 PLC
10 January 2022
 

Maven Income and Growth VCT 3 PLC and Maven Income and Growth VCT 4 PLC (the Companies)

 

Offers for Subscription - Early Investment Incentive

 

10 January 2022

 

On 20 September 2021, the Companies published a joint Prospectus (comprising a Securities Note, Registration Document and Summary) in relation to offers for subscription of new Ordinary Shares of 10p each (together the "Offers" and each an "Offer").

 

In the Prospectus, it was stated that all valid applications that were received (together with their relevant application monies) by the deadline of 12.00 noon on 28 January 2022 would be eligible to receive an Early Investment Incentive discount under the Offers. Existing Shareholders (and their spouses or partners) in any of the Maven VCTs, including the Companies, at the time the application was received would benefit from an enhanced rate of discount in recognition of their continued support for the Maven VCTs. The levels of discount to be applied would be:

 

· 1.5% of the application amount for Existing Shareholders; and

· 1.25% of the application amount for New Investors.

 

It was also stated that each Company could, in consultation with Maven Capital Partners UK LLP (Maven) and in their absolute discretion, extend the deadline by which applications must be received to be eligible for the Early Investment Incentive under its Offer.

 

The Board of each Company confirms that the deadline by which applications must be received to be eligible for the Early Investment Incentive under their Company's respective Offer has been extended until close of business on Wednesday 2 February 2022. Furthermore, it is anticipated that both Companies will make initial allotments of new Ordinary Shares under their respective Offers as soon as practicable after that date.

 

Further information

 

Any enquiries in respect of the Offers, or requests for copies of the Prospectus documents (available free of charge), should be directed to:

 

Maven Capital Partners UK LLP

Kintyre House

205 West George Street

Glasgow

G2 2LW

 

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

 

Downloadable versions of the Prospectus documents are available from the Maven website at: www.mavencp.com/vctoffer.

Maven Capital Partners UK LLPSecretary

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRFLFSFLIIILIF
Date   Source Headline
20th May 202210:03 amRNSIssue of Equity
13th May 20223:24 pmRNSStatement re Dividend Investment Scheme
12th May 20223:19 pmRNSNet Asset Value(s)
11th May 20222:01 pmRNSResult of AGM & Directorate Change
26th Apr 202212:34 pmRNSIssue of Supplementary Prospectus
5th Apr 20226:30 pmRNSIssue of Equity
23rd Mar 20225:10 pmRNSDirector/PDMR Shareholding
23rd Mar 20225:05 pmRNSIssue of Equity
22nd Mar 20223:23 pmRNSAnnual Financial Report
16th Mar 20223:32 pmRNSTransaction in Own Shares
15th Mar 20223:09 pmRNSTransaction in Own Shares
11th Mar 202211:41 amRNSIssue of Equity - Dividend Investment Scheme
10th Mar 202211:30 amRNSIssue of Equity
10th Mar 202211:20 amRNSStatement re Dividend Investment Scheme
10th Mar 202211:04 amRNSNet Asset Value and Proposed Final Dividend
18th Feb 20225:32 pmRNSIssue of Equity - Replacement Announcement
7th Feb 202212:49 pmRNSDirector/PDMR Shareholding
7th Feb 202212:48 pmRNSDirector/PDMR Shareholding
7th Feb 202210:51 amRNSIssue of Equity
4th Feb 20229:46 amRNSNet Asset Value(s)
31st Jan 20224:25 pmRNSStatement re Offer for Suscription
10th Jan 202212:43 pmRNSStatement re Offer for Subscription
5th Jan 202210:35 amRNSDividend Declaration
2nd Dec 20213:37 pmRNSTransaction in Own Shares
11th Nov 20213:25 pmRNSNet Asset Value(s)
20th Oct 20214:44 pmRNSResult of General Meeting
1st Oct 20219:22 amRNSIssue of Equity
28th Sep 20213:22 pmRNSStatement re Dividend Investment Scheme
20th Sep 20215:42 pmRNSStatement re Change of Registrar
20th Sep 20215:21 pmRNSPublication of a Prospectus
7th Sep 20214:47 pmRNSTransaction in Own Shares
31st Aug 20213:27 pmRNSTransaction in Own Shares
27th Aug 20213:23 pmRNSHalf-year Report
24th Aug 20213:42 pmRNSTransaction in Own Shares
23rd Aug 20213:14 pmRNSTransaction in Own Shares
19th Aug 20213:04 pmRNSStatement re NAV and Interim Dividend
16th Jun 20213:16 pmRNSStatement re Offer for Subscription
24th May 20214:45 pmRNSTransaction in Own Shares
21st May 202111:02 amRNSIssue of Equity
17th May 20214:32 pmRNSStatement re Dividend Investment Scheme
12th May 20214:08 pmRNSNet Asset Value(s)
12th May 202112:37 pmRNSResult of AGM
9th Apr 20215:48 pmRNSAnnual Financial Report
24th Feb 20214:20 pmRNSTransaction in Own Shares
23rd Feb 20214:18 pmRNSTransaction in Own Shares
17th Feb 20214:37 pmRNSStatement re NAV and Final Dividend
8th Dec 20203:27 pmRNSTransaction in Own Shares
17th Nov 20204:26 pmRNSTransaction in Own Shares
16th Nov 20204:52 pmRNSTransaction in Own Shares
11th Nov 20205:01 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.